Trial reportJournal of cosmetic dermatology2025
Efficacy and Safety of Rb-bFGF in Hair Transplantation: A Prospective and Comparative Study.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles of human transformed skin-derived precursors containing miR-221-3p promote hair growth through DKK2-mediated Wnt/Bioengineering & translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis prospective randomized controlled trial aimed to evaluate the clinical value of recombinant bovine basic fibroblast growth factor (rb-bFGF)-based combined therapy in hair transplantation, focusing on its optimization effects on follicle survival rate, postoperative hair-loss dynamics, complication control, and patient satisfaction.
methodsSixty patients with moderate-to-severe androgenetic alopecia were randomly assigned to either an rb-bFGF group or a control group. In the rb-bFGF group, harvested follicles were intraoperatively immersed in an rb-bFGF-enriched solution and patients received postoperative topical rb-bFGF gel for 3 weeks, in addition to baseline medications and minoxidil. Control group follicles were stored in saline, with postoperative minoxidil alone. Quantitative assessments include measurements of hair follicle viability and hair density at 3, 6, and 12 months postoperatively. Patient satisfaction was assessed using a three-level scale, and complication rates were recorded.
resultsThe rb-bFGF group demonstrated superior outcomes compared with controls, including higher 12-month follicle survival (91.1% vs. 81.0%), lower hair-loss rate (11.6% vs. 22.7%), greater patient satisfaction (96.7% vs. 80.0%), and fewer complications (20.0% vs. 85.3%). All differences were statistically significant (p < 0.001).
conclusionIntraoperative follicle immersion and postoperative topical application of rb-bFGF significantly enhance graft survival, reduce early hair loss, decrease complications, and improve overall outcomes in hair transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.